Advertisement

Non-invasive diagnosis

  • David E Neal

Abstract

Non-invasive testing for bladder cancer has been carried out for many years by means of urine testing for blood, the presence of malignant cells on cytological examination and assessment of DNA ploidy in voided urine or bladder washings.

Keywords

Bladder Cancer Transitional Cell Carcinoma Invasive Bladder Cancer Urine Cytology Nuclear Matrix Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cancer Statistics Registration (1988) OPCS — A publication of the government statistical service.Google Scholar
  2. 2.
    Britton JP (1993) Effectiveness of haematuria clinics. British Journal of Urology 71: 247–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Murphy WM, Riveral-Ramirez I, Medina CA, Wright NJ and Wajsman Z (1997) The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. Journal of Urology 158: 2102–6.PubMedCrossRefGoogle Scholar
  4. 4.
    D’Hallewin MA and Baert L (1996) Initial evaluation of the bladder tumour antigen test in superficial bladder cancer. Journal of Urology 155: 475–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Ramakumar S, Bhuiyan J, Besse JA et al. (1999) Comparison of screening methods in detection of bladder cancer. Journal of Urology 161: 388–94.PubMedCrossRefGoogle Scholar
  6. 6.
    Sarosdy MF, de Vere White RW, Soloway MS et al. (1995) Resulsts of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. Journal of Urology 154: 379–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Leyh H, Hall R, Mazeman E and Blumenstein BA (1997) Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology 50: 49–53.PubMedCrossRefGoogle Scholar
  8. 8.
    The UK and Republic of Ireland Bladder Tumour Antigen Study Group (1997) The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. British Journal of Urology 79: 362–6.Google Scholar
  9. 9.
    Leyh H, Marberger M, Conort P et al. (1999) Comparison of the BTA stat (TM) test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 35: 52–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Sarosdy MF, Hudson MA, Ellis WJ et al. (1997) Improved detection of recurrent bladder cancer using the Bard BTA STAT test. Urology 50: 349–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Pode D, Shapiro A, Wald M, Nativ O, Laufer M and Kaver I (1999) Non-invasive detection of bladder cancer with the BTA STAT test. Journal of Urology 161: 443–6.PubMedCrossRefGoogle Scholar
  12. 12.
    UK and Republic of Ireland BTA Study Group (1997) British Journal of Urology 79(suppl.4): 64.Google Scholar
  13. 13.
    Thomas L, Leyh H, Marberger M et al. (1999) Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 45: 472–7.PubMedGoogle Scholar
  14. 14.
    Leyh H, Marberger M, Conort P et al. (1999) Comparison of the BTA stat™ test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 35: 52–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Schmetter BS, Habicht KK, Lamm DL et al. (1977) A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. Journal of Urology 158: 801–5.CrossRefGoogle Scholar
  16. 16.
    Shelfo SW and Soloway MS (1997) The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 15: 107–11. AU: Stampfer DS, Carpinito GA, Rodriguez-Villanueva J and Willsey LW.PubMedCrossRefGoogle Scholar
  17. 17.
    Dinney CP, Grossman HB, Fritsche HA and McDougal WS (1998) Evaluation of NMP-22 in the detection of transitional cell carcinoma of the bladder. Journal of Urology 159: 394–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Landman J, Chang Y, Kavaler E, Droller MJ and Liu BCS (1998) Sensitivity and specificity of NMP-22, telomerase and BTA in the detection of human bladder cancer. Urology 52: 398–402.PubMedCrossRefGoogle Scholar
  19. 19.
    Sharma S, Zippe CD, Pandrangi L, Nelson D and Agarwal A (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP-22 and BTA stat. Journal of Urology 162: 53–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Ahrendt SA, Chow JT, Xu LH et al. (1999) Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Institute 91: 332–9.CrossRefGoogle Scholar
  21. 21.
    Linn JF, Lango M, Halachmi S, Schoenberg MP and Sidransky D (1997) Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer 74: 625–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Steiner G, Schoenberg MP, Linn JF, Mao L and Sidransky D (1997) Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 3: 621–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Mao L, Schoenberg MP, Scicchitano M et al. (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271: 659–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Dalbagni G, Han W, Zhang ZF et al. (1997) Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res 3: 1593–8.PubMedGoogle Scholar
  25. 25.
    Hotakainen K, Lintula S, Stenman J, Rintala E, Lindell O and Stenman UH (1999) Detection of messenger RNA for the beta-subunit of chorionic gonadotrophin in urinary cells from patients with transitional cell carcinoma of the bladder by reverse transcription-polymerase chain reaction. Int J Cancer 84: 304–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Mian C, Pycha A, Wiener H, Haitel A, Lodde M and Marberger M (1999) Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. Journal of Urology 161: 1486–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S and Kamidono S (1998) Urinary cytology and competitive reverse transcriptase polymerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer. Journal of Urology 160: 2004–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G and Marberger M(1998) Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? Journal of Urology 159: 1876–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Righi E, Rossi G, Ferrari G et al. (1997) Does p53 immunostaining improve diagnostic accuracy in urine cytology? Diagnostic Cytopathol 17: 436–9.CrossRefGoogle Scholar
  30. 30.
    Parmar MK, Freedman LS, Hargreave TB and Tolley DA (1989) Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Journal of Urology 142: 284–8.PubMedGoogle Scholar
  31. 31.
    Hall RR, Parmar MK, Richards AB and Smith PH (1994) Proposal for changes in cystoscopic follow-up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 308: 257–60.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2007

Authors and Affiliations

  • David E Neal
    • 1
  1. 1.Department of Oncology, University of CambridgeAddenbrooke’s HospitalCambridgeUK

Personalised recommendations